A Novel Microphysiological Colon Platform to Decipher Mechanisms Driving Human Intestinal Permeability.
Interleukin 22
Leaky Gut
Organ-on-Chip
Organoids
Journal
Cellular and molecular gastroenterology and hepatology
ISSN: 2352-345X
Titre abrégé: Cell Mol Gastroenterol Hepatol
Pays: United States
ID NLM: 101648302
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
10
2020
revised:
03
07
2021
accepted:
06
07
2021
pubmed:
21
7
2021
medline:
29
3
2022
entrez:
20
7
2021
Statut:
ppublish
Résumé
The limited availability of organoid systems that mimic the molecular signatures and architecture of human intestinal epithelium has been an impediment to allowing them to be harnessed for the development of therapeutics as well as physiological insights. We developed a microphysiological Organ-on-Chip (Emulate, Inc, Boston, MA) platform designed to mimic properties of human intestinal epithelium leading to insights into barrier integrity. We combined the human biopsy-derived leucine-rich repeat-containing G-protein-coupled receptor 5-positive organoids and Organ-on-Chip technologies to establish a micro-engineered human Colon Intestine-Chip (Emulate, Inc, Boston, MA). We characterized the proximity of the model to human tissue and organoids maintained in suspension by RNA sequencing analysis, and their differentiation to intestinal epithelial cells on the Colon Intestine-Chip under variable conditions. Furthermore, organoids from different donors were evaluated to understand variability in the system. Our system was applied to understanding the epithelial barrier and characterizing mechanisms driving the cytokine-induced barrier disruption. Our data highlight the importance of the endothelium and the in vivo tissue-relevant dynamic microenvironment in the Colon Intestine-Chip in the establishment of a tight monolayer of differentiated, polarized, organoid-derived intestinal epithelial cells. We confirmed the effect of interferon-γ on the colonic barrier and identified reorganization of apical junctional complexes, and induction of apoptosis in the intestinal epithelial cells as mediating mechanisms. We show that in the human Colon Intestine-Chip exposure to interleukin 22 induces disruption of the barrier, unlike its described protective role in experimental colitis in mice. We developed a human Colon Intestine-Chip platform and showed its value in the characterization of the mechanism of action of interleukin 22 in the human epithelial barrier. This system can be used to elucidate, in a time- and challenge-dependent manner, the mechanism driving the development of leaky gut in human beings and to identify associated biomarkers.
Sections du résumé
BACKGROUND & AIMS
The limited availability of organoid systems that mimic the molecular signatures and architecture of human intestinal epithelium has been an impediment to allowing them to be harnessed for the development of therapeutics as well as physiological insights. We developed a microphysiological Organ-on-Chip (Emulate, Inc, Boston, MA) platform designed to mimic properties of human intestinal epithelium leading to insights into barrier integrity.
METHODS
We combined the human biopsy-derived leucine-rich repeat-containing G-protein-coupled receptor 5-positive organoids and Organ-on-Chip technologies to establish a micro-engineered human Colon Intestine-Chip (Emulate, Inc, Boston, MA). We characterized the proximity of the model to human tissue and organoids maintained in suspension by RNA sequencing analysis, and their differentiation to intestinal epithelial cells on the Colon Intestine-Chip under variable conditions. Furthermore, organoids from different donors were evaluated to understand variability in the system. Our system was applied to understanding the epithelial barrier and characterizing mechanisms driving the cytokine-induced barrier disruption.
RESULTS
Our data highlight the importance of the endothelium and the in vivo tissue-relevant dynamic microenvironment in the Colon Intestine-Chip in the establishment of a tight monolayer of differentiated, polarized, organoid-derived intestinal epithelial cells. We confirmed the effect of interferon-γ on the colonic barrier and identified reorganization of apical junctional complexes, and induction of apoptosis in the intestinal epithelial cells as mediating mechanisms. We show that in the human Colon Intestine-Chip exposure to interleukin 22 induces disruption of the barrier, unlike its described protective role in experimental colitis in mice.
CONCLUSIONS
We developed a human Colon Intestine-Chip platform and showed its value in the characterization of the mechanism of action of interleukin 22 in the human epithelial barrier. This system can be used to elucidate, in a time- and challenge-dependent manner, the mechanism driving the development of leaky gut in human beings and to identify associated biomarkers.
Identifiants
pubmed: 34284165
pii: S2352-345X(21)00145-4
doi: 10.1016/j.jcmgh.2021.07.004
pmc: PMC8551844
pii:
doi:
Substances chimiques
Biomarkers
0
Interleukins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1719-1741Subventions
Organisme : Arthritis Research UK
ID : CC2021
Pays : United Kingdom
Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Références
J Immunol. 2003 Dec 1;171(11):6164-72
pubmed: 14634132
Nat Rev Immunol. 2014 May;14(5):329-42
pubmed: 24751956
J Immunol. 2003 Nov 15;171(10):5034-41
pubmed: 14607900
Am J Respir Cell Mol Biol. 2011 Mar;44(3):369-76
pubmed: 20463292
Nat Biotechnol. 2014 Aug;32(8):760-72
pubmed: 25093883
Mucosal Immunol. 2016 Mar;9(2):539-49
pubmed: 26329427
Gastroenterology. 2006 Oct;131(4):1153-63
pubmed: 17030185
J Immunol. 2017 Oct 1;199(7):2333-2342
pubmed: 28842466
Gastroenterology. 2015 Dec;149(7):1731-1741.e3
pubmed: 26327134
Inflamm Bowel Dis. 2014 Aug;20(8):1426-34
pubmed: 24991784
Nat Rev Drug Discov. 2014 Jan;13(1):21-38
pubmed: 24378801
Nat Rev Immunol. 2014 Mar;14(3):141-53
pubmed: 24566914
Cell Host Microbe. 2017 Jun 14;21(6):671-681.e4
pubmed: 28618266
Gut. 1995 May;36(5):724-30
pubmed: 7541009
Nat Med. 2008 Mar;14(3):282-9
pubmed: 18264109
J Crohns Colitis. 2013 Apr;7(3):248-55
pubmed: 22784949
Immunity. 2007 Oct;27(4):647-59
pubmed: 17919941
Nature. 2009 May 14;459(7244):262-5
pubmed: 19329995
Am J Pathol. 2005 Feb;166(2):409-19
pubmed: 15681825
Nature. 2015 Dec 24;528(7583):560-564
pubmed: 26649819
Cell Mol Gastroenterol Hepatol. 2020;9(3):507-526
pubmed: 31778828
Nat Clin Pract Gastroenterol Hepatol. 2006 Jul;3(7):390-407
pubmed: 16819502
J Clin Invest. 1989 Feb;83(2):724-7
pubmed: 2492310
Cell Mol Gastroenterol Hepatol. 2019;7(3):641-653
pubmed: 30659943
J Anat. 2008 Jun;212(6):879-86
pubmed: 18510513
J Exp Med. 2011 May 9;208(5):1027-40
pubmed: 21518800
J Clin Invest. 2008 Feb;118(2):534-44
pubmed: 18172556
Gastroenterology. 2011 Nov;141(5):1762-72
pubmed: 21889923
J Immunol. 2014 Oct 1;193(7):3779-91
pubmed: 25187663
Gut. 2020 Mar;69(3):578-590
pubmed: 31792136
Scand J Gastroenterol Suppl. 1993;196:3-6
pubmed: 8341988
Microbiome. 2019 Mar 20;7(1):43
pubmed: 30890187
Cancer Immunol Res. 2015 Nov;3(11):1227-35
pubmed: 26130064
EMBO J. 2015 May 5;34(9):1149-63
pubmed: 25792515
Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12768-73
pubmed: 23781104
Biochem Pharmacol. 2013 Feb 1;85(3):396-403
pubmed: 23153456
Elife. 2020 Jan 14;9:
pubmed: 31933478
Cell Mol Gastroenterol Hepatol. 2017 Nov 03;5(2):113-130
pubmed: 29693040
Mucosal Immunol. 2014 Jan;7(1):101-13
pubmed: 23653115
Nat Rev Mol Cell Biol. 2014 Dec;15(12):786-801
pubmed: 25415508
Sci Rep. 2018 Feb 13;8(1):2871
pubmed: 29440725
Eur J Biochem. 1999 Oct;265(2):501-23
pubmed: 10504381
Am J Physiol Gastrointest Liver Physiol. 2006 Apr;290(4):G827-38
pubmed: 16537974
Gut. 2019 Aug;68(8):1516-1526
pubmed: 31076401
Eur J Immunol. 2006 May;36(5):1309-23
pubmed: 16619290
Stem Cell Reports. 2017 Dec 12;9(6):1976-1990
pubmed: 29153987
Int J Mol Med. 2019 Apr;43(4):1657-1668
pubmed: 30816423
Front Physiol. 2016 Jan 29;7:9
pubmed: 26858653
Cell Mol Gastroenterol Hepatol. 2016 Jan 1;2(1):48-62.e3
pubmed: 26855967
Cell Stem Cell. 2017 Feb 2;20(2):177-190.e4
pubmed: 27939219
Cell Rep. 2017 Jan 3;18(1):263-274
pubmed: 28052255
Science. 2013 Jun 7;340(6137):1190-4
pubmed: 23744940
ACS Infect Dis. 2018 Jan 12;4(1):46-52
pubmed: 29094594
Immunity. 2010 Mar 26;32(3):392-402
pubmed: 20303298
J Clin Invest. 2019 Nov 1;129(11):4691-4707
pubmed: 31566580
J Immunol. 2017 Nov 1;199(9):3316-3325
pubmed: 28939759
Annu Rev Physiol. 2017 Feb 10;79:291-312
pubmed: 28192061
Clin Pharmacol Ther. 2019 Jan;105(1):177-189
pubmed: 29952004
Eur J Pharm Biopharm. 2015 Aug;94:194-206
pubmed: 26026287